BRAF and metastatic colorectal cancer: Given that metastatic colorectal cancer (mCRC) patients underwent genomic profiling for clinically actionable mutations such as KRAS, NRAS, and BRAF analysis routinely with a clinically validated COBAS panel, we rationalized separating this cohort from the remaining patients.